
													
															
															Year
															DEALS // DEV.
															Country
															
															Therapeutic Area
															Study Phase
															Deal Type
															Product Type
															Dosage Form
															Lead Product
															Target

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : BMB-101
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Bright Minds Biosciences
Deal Size : Undisclosed
Deal Type : Collaboration
Firefly Neuroscience Collaborates with Bright Minds for AI-Based Study
Details : The collaboration aims to analyze the data from its first-in-human Phase 1 of BMB-101, a highly selective 5-HT2C, Gq-protein biased agonist, for neuropsychiatric disorders and epilepsy.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
October 16, 2024
Lead Product(s) : BMB-101
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Bright Minds Biosciences
Deal Size : Undisclosed
Deal Type : Collaboration

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : SP-624
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Arrivo BioVentures
Deal Size : Inapplicable
Deal Type : Inapplicable
Firefly Neuroscience Uses Brain Analytics Platform in Phase 1 SP-624 Study
Details : SP-624 is a first-in-class SIRT6 activator, small molecule drug candidate, which is being evaluated for the treatment of patients with major depressive disorder.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 15, 2024
Lead Product(s) : SP-624
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Arrivo BioVentures
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Ibudilast,Bumetanide
Therapeutic Area : Neurology
Study Phase : Phase I
Recipient : Stalicla
Deal Size : Undisclosed
Deal Type : Partnership
Details : STALICLA and Firefly will leverage their technological platforms including the DEPI and BNA platform respectively to further advance EEG validation in two upcoming Phase 2 clinical trials including STALICLA’s lead asset STP1, a tailored treatment candi...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
March 27, 2023
Lead Product(s) : Ibudilast,Bumetanide
Therapeutic Area : Neurology
Highest Development Status : Phase I
Recipient : Stalicla
Deal Size : Undisclosed
Deal Type : Partnership
